{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:50:41Z","timestamp":1768801841267,"version":"3.49.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.amjcard.2024.05.001","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T15:12:06Z","timestamp":1715267526000},"page":"183-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cardiovascular and Renal Benefit of Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes"],"prefix":"10.1016","volume":"223","author":[{"given":"Steven Ho Man","family":"Lam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uazman","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Yoke Hong","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2024.05.001_bib0001","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","article-title":"Sodium\u2013glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus","volume":"16","author":"Scheen","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.amjcard.2024.05.001_bib0002","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjcard.2024.05.001_bib0003","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.05.001_bib0004","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1681\/ASN.2018010103","article-title":"Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial","volume":"29","author":"Wanner","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2024.05.001_bib0005","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2024.05.001_bib0006","doi-asserted-by":"crossref","unstructured":"Eleftheriadou A, Riley D, Zhao SS, Austin P, Hern\u00e1ndez G, Lip GYH, Jackson TL, Wilding JPH, Alam U. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database [published online April 8, 2024]. Diabetologia doi:10.1007\/s00125-024-06132-5.","DOI":"10.1007\/s00125-024-06132-5"},{"key":"10.1016\/j.amjcard.2024.05.001_bib0007","doi-asserted-by":"crossref","unstructured":"Kim JH, Lyu YS, Kim B, Kim MK, Kim SY, Baek KH, Song KH, Han K, Kwon HS. Cardiorenal outcomes and mortality after sodium-glucose cotransporter-2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history [published online April 21, 2024]. Diabetes Obes Metab doi:10.1111\/dom.15565.","DOI":"10.1111\/dom.15565"},{"key":"10.1016\/j.amjcard.2024.05.001_bib0008","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1111\/dom.15185","article-title":"All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes","volume":"25","author":"Riley","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2024.05.001_bib0009","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.05.001_bib0010","first-page":"772","volume":"77","author":"Committee","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.05.001_bib0011","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.amjcard.2024.04.011","article-title":"Kidney and cardiovascular effectiveness of empagliflozin compared with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes","volume":"221","author":"Edmonston","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2024.05.001_bib0012","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3390\/ijms24010658","article-title":"Current knowledge on the pathophysiology of lean\/normal-weight type 2 diabetes","volume":"24","author":"Salvatore","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.amjcard.2024.05.001_bib0013","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.clinthera.2023.07.026","article-title":"Metformin and SGLT2i as first-line combination therapy in type 2 diabetes: a real-world study with a focus on ethnicity","volume":"45","author":"Anson","year":"2023","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjcard.2024.05.001_bib0014","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/nyas.12098","article-title":"Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States","volume":"1281","author":"Ma","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.amjcard.2024.05.001_bib0015","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/oby.20997","article-title":"Ethnic differences in associations between fat deposition and incident diabetes and underlying mechanisms: the SABRE study","volume":"23","author":"Eastwood","year":"2015","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.amjcard.2024.05.001_bib0016","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12933-023-01938-w","article-title":"Machine learning profiles of cardiovascular risk in patients with diabetes mellitus: the Silesia Diabetes-Heart Project","volume":"22","author":"Kwiendacz","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjcard.2024.05.001_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248636","article-title":"Prediction of risk of acquiring urinary tract infection during hospital stay based on machine-learning: a retrospective cohort study","volume":"16","author":"M\u00f8ller","year":"2021","journal-title":"PLoS One"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924003400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924003400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T21:11:09Z","timestamp":1731532269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914924003400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":17,"alternative-id":["S0002914924003400"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.05.001","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular and Renal Benefit of Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.04.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}